Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Glutamate (Metabotropic) Group III Receptors
More Information »Metabotropic Glutamate (mGlu) group III receptors are members of the metabotropic class of glutamate receptors, which also includes mGlu group I and mGlu group II receptors. Group III receptors are divided into four subtypes, mGlu4, mGlu6, mGlu7 and mGlu8.
Glutamate (Metabotropic) Group III Receptor Products
Agonists |
|
Cat.No. |
Product Name / Activity |
| 1111 | ACPT-I |
| Group III mGlu agonist | |
| 2385 | AMN 082 dihydrochloride |
| The first selective mGlu7 agonist | |
| 0103 | L-AP4 |
| Selective group III mGlu agonist | |
| 4119 | Cinnabarinic acid |
| Selective mGlu4 agonist | |
| 1394 | (RS)-3,4-DCPG |
| Potent systemically active anticonvulsant. Racemate of (S)-3,4-DCPG (Cat. No. 1302) | |
| 1302 | (S)-3,4-DCPG |
| Potent, selective mGlu8a agonist | |
| 3330 | NPEC-caged-(S)-3,4-DCPG |
| Caged (S)-3,4-DCPG | |
| 0238 | O-Phospho-L-serine |
| Group III mGlu agonist | |
| 1220 | (RS)-PPG |
| Potent, selective mGlu8 agonist | |
| 3248 | VU 0155041 |
| Potent, positive allosteric mGlu4 agonist | |
| 3311 | VU 0155041 sodium salt |
| Potent, positive allosteric mGlu4 agonist. Sodium salt of VU 0155041 (Cat. No. 3248) | |
| 3249 | Z-Cyclopentyl-AP4 |
| Group III mGlu agonist (mGlu4 > mGlu8 > mGlu7) | |
Antagonists |
|
Cat.No. |
Product Name / Activity |
| 0972 | CPPG |
| Very potent group III mGlu antagonist | |
| 1209 | LY 341495 |
| Group II/III antagonist | |
| 4062 | LY 341495 disodium salt |
| Disodium salt of LY 341495 (Cat. No. 1209) | |
| 3272 | (±)-LY 395756 |
| mGlu group III antagonist | |
| 0711 | MAP4 |
| Selective group III mGlu antagonist. Also potent group II/group III mGlu agonist | |
| 2963 | MMPIP hydrochloride |
| Potent, allosteric mGlu7-selective antagonist | |
| 0853 | MPPG |
| Group III/group II mGlu antagonist. More selective for group III than group II | |
| 0803 | MSOP |
| Specific group III mGlu antagonist | |
| 0854 | MSPG |
| Group III/group II mGlu antagonist | |
| 1369 | UBP1112 |
| Group III mGlu antagonist | |
Modulators |
|
Cat.No. |
Product Name / Activity |
| 1212 | MPEP hydrochloride |
| Positive allosteric modulator at mGlu4 and mGlu5 antagonist | |
| 1214 | SIB 1893 |
| Positive allosteric modulator at mGlu4 and mGlu5 antagonist | |
| 4370 | TC-N 22A |
| Potent, selective mGlu4 positive allosteric modulator | |
| 4259 | TCN 238 |
| Positive allosteric modulator of mGlu4 | |
| 3707 | VU 0361737 |
| Selective positive allosteric modulator at mGlu4 | |
| 4371 | VU 0364439 |
| Positive allosteric modulator at mGlu4 | |
| 4469 | VU 0364770 |
| Positive allosteric modulator at mGlu4 | |
Ligand Sets |
|
Cat.No. |
Product Name / Activity |
| 1828 | Group III mGlu Receptor Tocriset™ |
| Selection of 5 group III mGlu receptor ligands (Cat. Nos. 0103, 1220, 0972, 0803 and 1209) | |
| 1829 | Mixed mGlu Receptor Tocriset™ |
| Selection of 5 mixed mGlu receptor ligands (Cat. Nos. 0805, 0975, 0103, 0337 and 1209) | |
Related Categories
Quick Order
Find multiple products by catalog number
Pain Research Guide
Reserve your free copy
Highlights over 280 products for Pain research. Reserve copy
mGlu Receptors Review
Written by Francine Acher, an expert in the field. Request a copy or view PDF today.
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Therapeutic Strategies in Schizophrenia
Written by J. Lieberman
'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.
Tocris Events
Win a Kindle
11th Congress of the French Neuroscience Society
May 21 - 24, 2013
Lyon, France
Booth Number: 32